1. Scrip
  2. >>Business
  3. >>Financing

Galera Raises $150m To Take Lead Drug From Phase III To NDA Submission

 
• By Mandy Jackson

Galera garnered $70m in Series C venture capital and $80m through a royalty deal tied to GC4419 and a follow-up drug for the treatment of severe oral mucositis caused by radiation therapy with an initial focus on head and neck cancer patients.

Two businessmen shaking hands during a meeting in the office, success, dealing, greeting & business partner concepts - soft light.

Galera Therapeutics Inc. raised $150m in private funding, including $70m in Series C venture capital and $80m from a royalty financing, to develop its lead drug candidate from Phase III through a US FDA filing for its first indication – the treatment of radiation-induced severe oral mucositis (SOM) in head and neck cancer patients. Additional SOM and cancer treatment indications also are being pursued.

Malvern, Penn.-based Galera is developing multiple small molecule dismutase mimetics, which mimic the activity of human superoxide dismutase enzymes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.